Table 1.
MPS type | Number of patients | Percentage of all MPS (%) | Incidence per 100,000 | Prevalence per 1,000,000 |
---|---|---|---|---|
MPS I (Hurler Syndrome) | 207 | 26.23 | 0.26 | 0.70 |
MPS II (Hunter Syndrome) | 207 | 26.23 | 0.26 | 0.70 |
MPS III (Sanfilippo Syndrome) | 210 | 26.60 | 0.26 | 0.71 |
Type A | 153 | 19.40 | 0.19 | 0.52 |
Type B | 40 | 5.10 | 0.05 | 0.14 |
Type C | 12 | 1.50 | 0.015 | 0.04 |
Type D | 0 | 0.00 | 0 | 0 |
MPS IV (Morquio Syndrome) | 113 | 14.32 | 0.14 | 0.38 |
Type Aa | 87 | 11.00 | 0.11 | 0.29 |
Type B | 3 | 0.40 | 0.004 | 0.01 |
MPS VI (Maroteaux-Lamy Syndrome) | 31 | 3.92 | 0.04 | 0.11 |
MPS VIIb (Sly Syndrome) | 21 | 2.70 | 0.027 | 0.07 |
MPS IX (Hyaluronidase deficiency) | 0 | 0.00 | 0 | 0 |
All Mucopolysaccharidoses | 789 | 100.00 | 0.98 | 2.67 |
Some patients are reported as MPS III or IV while there is no information on the sub-type
aBased on information from the MPS IVA International registry [7]
bBased on information provided by Ultragenyx Pharmaceuticals